Recent patents on oral vaccine design

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 3, Issue 3, 2009, Pages 179-193

  Mangal, Sharad ^a   Garg, Neeraj K ^a   Mounavya, Aligeti ^b   Sahu, Tejram ^c   Tyagi, Rajeev K ^c,d  

^a DR H S GOUR UNIVERSITY   (India)

^b AMITY UNIVERSITY   (India)

^c INSTITUT PASTEUR   (France)

^d CH CHARAN SINGH UNIVERSITY   (India)

Author keywords

Drug delivery system; Mucosal immunity; Oral vaccination; Tolerance

Indexed keywords

ALLERGEN; ANTIGEN; ARCHAEOSOME; BILOSOME; BOVINE SERUM ALBUMIN; COCHLEATE; DNA; DRUG CARRIER; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; ISCOM; LIPID; LIPOSOME; LIVE VACCINE; MICROPARTICLE; NAKED DNA; NANOPARTICLE; NIOSOME; PEANUT ANTIGEN; POLYMER; PROTEASOME; PROTEIN; RECOMBINANT NEOSPORA CANINUM SRS2 ANTIGEN; TRIPLE VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIROSOME; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ANTIGENICITY; BACTERIAL GHOST; BACTERIAL MEMBRANE; BIODEGRADABILITY; BRAIN INFECTION; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; ENCAPSULATION; FOOD ALLERGY; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; INFLUENZA; LIPOSOMAL DELIVERY; MICROFLORA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATENT; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; VIRUS LIKE AGENT;

EID: 70349216997     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221409789104728     Document Type: Review

References (193)

1. McGhee JR, Mestecky J, Dertzbaugh MT, Elgridge JH, Hirasawa M, Kiyono H. The mucosal immune system: From fundamental concepts to vaccine development. Vaccine 1992; 10(2): 75-88.
2. Mestecky J, McGhee JR. ImmunoglobulinA (IgA): Molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol 1987; 40: 153-245.
3. Institute of Medicine. New vaccine development: Establishing priorities, diseases in developing countries. Washington, DC: National Academy Press 1986; II: 1-16.
4. Levine MM, Campbell JD. Mucosal immunization and needle-free injection devices. In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF, Eds. New Generation Vaccines, Marcel Dekker, Inc.: New York NY 2004; 393-399.
5. Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR. Transcutaneous immunization and immunostimulant strategies. Immunol Allergy Clin North Am 2003; 23: 787-813.
6. Bennett JV, Fernandez de CJ, Valdespino-Gomez JL, et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: Randomized trials in Mexican schoolchildren. Bull World Health Organ Suppl 2002; 80: 806-812.
7. Mastroeni P, Bowe F, Cahill R, Simmons C, Dougan G. Vaccines against gut pathogens. Gut 1999; 45(5): 633-635.
8. Bouvet JP, Decroix N, Pamonsinlapatham P. Stimulation of local antibody production: Parenteral or mucosal vaccination? Trends Immunol 2002; 23: 209-213.
9. Owen RL, Jones AL. Epithelial cell specialization within human Peyer's patches: An ultrastructural study of intestinal lymphoid follicles. Gastroenterology 1974; 66: 189-203.
10. Neutra MR, Mantis NJ, Kraehenbuhl JP. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol 2001; 2: 1004-1009.
11. Lee VHL, Davis SS, Illum L, Tomlinson E. Enzymatic barriers to peptide and protein absorption and the use of penetration enhancers to modify absorption. In: Davis SS, Ilium L, Tomlinson E, Eds. Delivery systems for peptide drugs. New York Plenum 1986; 87-104.
12. Pierce N, Cray W. Determinants of the localization, magnitude, and duration of a specific mucosal IgA plasma cell response in enterically immunized mice. J Immunol 1982; 128: 1311-1315.
13. Lange S, Nygren H, Svennerholm A, Holmgren J. Antitoxic cholera immunity in mice. Influence of antigen deposition on antitoxin-containing cells and protective immunity in different parts of the intestine. Infect Immunol 1980; 28: 17-23.
14. Mattingly JA, Waksmann BH. Immunological suppression after oral administration of antigen. I. Specific suppressor cells formed in Peyers patches after oral administration of sheep erythrocytes and their systemic migration. J Immunol 1978; 121(5): 1878-1883.
15. Russell-Jones GJ. Oral vaccine delivery. J Control Release 2000; 65: 49-54.
16. Mowat AM, Steel M, Worthey EA, Kewin PJ, Garside P. Inactivation of Th1 and Th2 cells by feeding ovalbumin. Ann NY Acad Sci 1996; 778: 122-132.
17. Gregerson DS, Obritsch WF, Donoso LA. Oral tolerance in experimental autoimmune uveoretinitis. Distinct mechanisms of resistance are induced by low dose vs high dose feeding protocols. J Immunol 1993; 151: 5751-5761.
18. Brandtzaeg P. Developement and basic mechanisms of human gut immunity. Nutr Rev 1998; 1993: S5-S18.
19. Guy-Grand D, Griscelli C, Vassalli P. The gut-associated lymphoid system: Nature and properties of the large dividing cells. Eur J Immunol 1974; 4: 435-443.
20. Roux ME, McWilliams M, Phillips-Quagliata JM, Lamm ME. Differentiation pathways of Peyer's patch precursors of IgA plasma cells in the secretory immune system. Cell Immunol 1981; 61: 141-153.
21. Butcher EC, William M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol 1999; 72: 209-253.
22. 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MADCAM-1. Cell 1993; 74: 185-195.
23. Sonoda E, Matsumoto R, Hitoshi Y. Transforming growth factor beta induces IgA production and acts additively with interleukin-5 for IgA production. J Exp Med 1989; 170: 1415-1420.
24. McIntyre TM, Kehry MR, Snapper CM. Novel in vitro model for high rate of IgA class switching. J Immunol 1995; 154: 3156-3161.
25. Spalding DM, Williamson SI, Koopman WJ, McGhee JR. Preferential induction of polyclonal IgA secretion by murine Peyer's patch dendritic cell T cell mixtures. J Exp Med 1984; 160: 941-946.
26. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunization and adjuvants: A brief overview of recent advances and challenges. Vaccine 2003; 21: S89-S95.
27. Kompella UB, Lee VH. Delivery systems for penetration enhancement of peptide and protein drugs: Design considerations. Adv Drug Deliv Rev 2001; 46: 211-245.
28. Russell-Jones GJ. Use of Vitamin B12 conjugates to deliver protein drugs by the oral route. Crit Rev Ther Drug Carrier Syst 1998; 15: 557-586.
29. Fasano A. Modulation of intestinal permeability: An innovative method of oral drug delivery for the treatment of inherited and acquired human diseases. Mol Genet Metab 1998; 64: 12-18.
30. Lubitz W, Witte A, Eko FO, et al. Extended recombinant bacterial ghost system. J Biotechnol 1999; 73(2-3): 261-273.
31. Jalava K, Eko FO, Riedmann E, Lubitz W. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev Vacc 2003, 2: 45-51.
32. Jechlinger W, Haidinger W, Paukner S, et al. Bacterial ghosts as carrier and targeting systems for antigen delivery. Vaccine delivery strategies. In: Goebel W, Ed. Horizon Scientific Press: 2002; 163-184.
33. Miyanohara A, Imamura T, Araki M, Sugawara K, Ohtomo N, Matsubara K. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: Synthesis of two polypeptides translated from different initiation codons. J Virol 1986; 59: 176-180.
34. Delchambre M, Gheysen D, Thines D, et al. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J 1989; 8: 2653-2660.
35. Gheysen D, Jacobs E, de Foresta F, et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989; 59: 103-112.
36. French TJ, Marshall JJ, Roy P. Assembly of double-shelled, virus like particles of bluetongue virus by the simultaneous expression of four structural proteins. J Virol 1990; 64: 5695-5700.
37. Schirmbeck R, Böhm W, Reimann J. Virus-like particles induce MHC class Irestricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 1996; 39 (1-2): 111-119.
38. Paliard X, Liu Y, Wagner R, Wolf H, Baenziger J, Walker CM. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 2000: 16(3): 273-282.
39. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 2003; 100 (11): 6753-6758.
40. Sedlik C, Saron M, Sarraseca J, Casal I, Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci USA 1997; 94 (14): 7503-7508.
41. Gregoriadis, Ed. Liposome technology. 2nd ed., CRC Press: Boca Raton, FL 1992; III, 1-400.
42. Gould-Fogerite S, Mannino RJ. Mucosal and systemic immunization using cochleate and liposome vaccines. J Liposome Res 1996; 6: 357-379.
43. Mannino RJ, Gould-Fogerite S. Lipid matrix-based vaccines for mucosal and systemic immunization. In: Powell MF, Newman MJ, Eds. Vaccine Design: The subunit and adjuvant approach. Plenum Press: New York 1995; 363-387.
44. Kersten GF, Crommelin DJ. Liposomes and ISCOMs. Vaccine 2003; 21: 915-920.
45. Patel GB, Sprott GD. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. Crit Rev Biotechnol 1999; 19: 317-57.
46. Krishnan L, Dicaire CJ, Patel GB, Sprott GD. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: Comparison to conventional liposomes and alum. Infect Immun 2000; 68: 54-63.
47. Conlan JW, Krishnan L, Willick GE, Patel GB, Sprott GD. Immunization of mice with lipopeptide antigens encapsulated in novel liposomes prepared from the polar lipids of various Archaeobacteria elicits rapid and prolonged specific protective immunity against infection with the facultative intracellular pathogen, Listeria monocytogenes. Vaccine 2001; 19: 3509-3517.
48. Mowat AM, Maloy KJ. Immune stimulating complexes as vectors for oral immunization. In: O'Hagan DT, Ed. Novel delivery systems for oral vaccines. CRC Press: Boca Raton 1994; 207-240.
49. Morein B. The ISCOM: An immunostimulating system. Immunol Lett 1990; 25: 283-284.
50. Bungener L, Huckriede A, Wilschut J, Daemen T. Delivery of protein antigens to the immune system by fusion-active virosomes: A comparison with liposomes and ISCOMs. Biosci Rep 2002; 22: 323-338.
51. Brewer JM, Tetley L, Richmand J, Liew FY, Alexander J. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J Immunol 1998; 161: 4000-4007.
52. Hassan Y, Brewer JM, Alexander J, Jennings R. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems. Vaccine 1996; 4: 1581-1589.
53. Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 2001; 19(20-22): 2965-2974.
54. Brewer JM, Alexander J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology 1992; 75: 570-575.
55. O'Hagan DT, Singh M, Ulmer JB. Microparticle-based technologies for vaccines. Methods 2006; 40: 10-19.
56. O'Hagan DT, Rahman D, McGee JP, et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 1991; 73: 239-242.
57. O' Hagan H, Jeffery DT, Roberts MJ, McGee JP, Davis SS. Controlled release microparticles for vaccine development. Vaccine 1991; 9: 768-771.
58. Audran R, Peter R, Dannull J, et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003; 21: 1250-1255.
59. Men Y, Tamber H, Audran R, Gander B, Corradin G. Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres. Vaccine 1997; 15: 1405-1412.
60. Johansen P, Raynaud C, Yang M, Colston MJ, Tascon RE, Lowrie DB. Antimycobacterial immunity induced by a single injection of M. leprae Hsp65-encoding plasmid DNA in biodegradable microparticles. Immunol Lett 2003; 90: 81-85.
61. Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: A critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst 2005; 22: 419-464.
62. Lowe PJ, Temple CS. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: Protection against proteases and effect on intestinal absorption in rats. J Pharm Pharmacol 1994; 46: 547-552.
63. Mathiowitz E, Jacob JS, Jong YS, et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 1997; 386: 410-414.
64. Tobio M, Gref R, Sanchez A, Langer R, Alonso R. Stealth PLAPEG nanoparticles as protein carriers for nasal administration. Pharm Res 1998; 15: 270-275.
65. Pasetti MF, Levine MM, Sztein MB. Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar typhi live oral vaccines and live vectors. Vaccine 2003; 21: 401-418.
66. Eo SK, Yoon HA, Aleyas AG, et al. Systemic and mucosal immunity induced by oral somatic transgene vaccination against glycoprotein B of Pseudorabies virus using live attenuated Salmonella typhimurium. FEMS Immunol Med Microbiol 2006; 47: 451-461.
67. Wiedig CA, Kramer U, Garbom S, Wolf-Watz H, Autenrieth IB. Induction of CD8+ T cell responses by Yersinia vaccine carrier strains. Vaccine 2005; 23(10): 4984-4998.
68. Seegers JF. Lactobacilli as live vaccine delivery vectors: Progress and prospects. Trends Biotechnol 2002; 20: 505-515.
69. Lubitz, W., Szostak, M.: US5470573 (1997).
70. Lubitz, W., Haidinger, W.: PCT/EP02/07758 (2002).
71. Lubitz, W.: US20016177083 (2001).
72. Lubitz, W.: US20036610517 (2003).
73. Lubitz, W., Resch, S.: US20036596510 (2003).
74. Lubitz, W., Huter, V.: EP1158966 B1 (2003).
75. Lubitz, W., Harkness, R.: US5075223 (1991).
76. Lubitz, W., Paukner, S.: PCT/EP01/00864 (2001).
77. Jalava K, Eko FO, Riedmann E, Lubitz W. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev Vacc 2003, 2: 45-51.
78. Paukner S, Kohl G, Jalava K, Lubitz W. Sealed bacterial ghosts - novel targeting vehicles for advanced drug delivery of water-soluble substances. J Drug Target 2003; 11: 151-161.
79. Eko, FO, Mayr UB, Attridge SR, Lubitz W. Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. J Biotechnol 2000; 83: 115-123.
80. Panthel K, Jechlinger W, Matis A, et al. Generation of Helicobacter pylori Ghosts by PhiX Protein E-Mediated inactivation and their evaluation as vaccine candidates. Infect Immun 2003; 71(1): 109-116.
81. Huter V, Szostak MP, Gampfer J, et al. Bacterial ghosts as drug carrier and targeting vehicles. J Control Release 1999; 61(1-2): 51-63.
82. Mayr lB, Haller C, Haidinger W, Atrasheuskaya A, Lubitz EBW, Ignatyev G. Bacterial ghosts as an oral vaccine: A single dose of Escherichia coli O157: H7 Bacterial ghosts protects mice against lethal challenge. Infect Immun 2005;73(8): 4810-4817.
83. Dupuy C, Buzoni-Gatel D, Touzé A, Bout D, Coursaget P. Nasal immunization of mice with human Papilloma virus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 1999; 73(11): 9063-9071.
84. Zhang LF, Zhou J, Chen S, et al. HPV6b viruses like particles are potent immunogens without adjuvant in man. Vaccine 2000; 18(11-12): 1051-1058.
85. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human Papillomavirus type 16 vaccine. N Engl J Med 2002; 347(21): 1645-1651.
86. Santi L, Batchelor L, Huang Z, et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 2008; 26: 1846-1854.
87. Grgacic EV, Anderson DA. Virus-like particles: Passport to immune recognition. Methods 2006; 40: 60-65.
88. Vieira HL, Estêvão C, Roldão A, et al. Triple layered rotavirus VLP production: Kinetics of vector replication, mRNA stability and recombinant protein production. J Biotechnol 2005; 120: 72-82.
89. Ludwig C, Wagner R. Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol 2007; 18: 537-545.
90. Skountzou I, Quan FS, Gangadhara S, et al. Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol 2007; 81: 1083-1094.
91. Childers NK, Michalek SM. Liposomes. In: O'Hagan DT, Ed. Novel delivery systems for oral vaccines. CRC Press: Boca Raton, FL 1994; 175-205.
92. Jackson S, Mestecky J, Childers NK, Michalek SM. Liposomes containing anti-idiotypic antibodies: An oral vaccine to induce protective secretory immune response specific for pathogens of mucosal surfaces. Infect Immunol 1990; 58: 1932-1936.
93. Michalek SM, Childers NK, Katz J, et al. Liposomes and conjugate vaccines for antigen delivery and induction of mucosal immune responses. Adv Exp Med Biol 1992; 327: 191-198.
94. Childers NK, Denys FR, McGee NF, Michalek SM. Ultrastructural study of liposome uptake by M-cells of rat Peyer's patch: An oral vaccine system for delivery of purified antigen. Reg Immunol 1990; 3(1): 8-16.
95. Gregoriadis G. Immunological adjuvants: A role for lipoisomes. Immunol Today 1990; 11: 89-97.
96. Gregoriadis G, Ed. Liposome vaccines. J Liposome Res 1996; 6(2): 1-642.
97. Michaleck S, Osterhaus A, O'Hagan D, Gould-Fogerite S. Nonliving vaccines, liposomes, microparticles, Iscoms, and cochleates. In: McGhee JR, Ed. Mucosal Immunology. 2nd Ed. Marcel Dekker: New York 1998.
98. Iwanaga K, Ono S, Narioka K, et al. Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J Pharm Sci 1999; 88(2): 248-252.
99. Hirsh DJ, Lazaro N, Wright LR, et al. A new monofluorinated phosphatidylcholine forms interdigitated bilayers. Biophys J 1998; 75(4): 1858-1868.
100. Alving CR. Liposomal vaccines: Clinical status and immunological presentation for humoral and cellular immunity. Ann N Y Acad Sci 1995; 754: 143-152.
101. Katre NV. Liposome-based depot injection technologies: How versatile are they? Am J Drug Deliv 2004; 2: 213-227.
102. Meidenbauer N, Harris DT, Spitler LE, Whiteside TL. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 2000; 43: 88-100.
103. Venkatesan N, Vyas SP. Polysaccharide coated liposomes for oral immunization-development and characterization. Int J Pharm 2000; 203: 169-177.
104. Bacon, A.D., Laing, P., Gregoriadis, G., Caparros-wanderley, W.R.: US20050220858A1 (2005).
105. Chen, H., Langer, R.S.: US20026387397 (2002).
106. Gould-Fogerite S, Mannino RJ. Rotary dialysis: Its application to the production of large liposomes and large proteoliposomes (protein-lipid vesicles) with high encapsulation efficiency and efficient reconstitution of membrane proteins. Anal Biochem 1985; 148: 15-25.
107. Gould-Fogerite S, Mazurkiewicz JE, Bhisitkul D, Mannino RJ. The reconstitution of biologically active glycoproteins into large liposomes: Use as a delivery vehicle to animal cells. In: Kim CH, Diwan J, Tedeschi H, Salerno JJ, Eds. Advances in membrane biochemistry and bioenergetics. Plenum Publishing Corp.: New York 1987; 569-586.
108. Gould-Fogerite S, Mazurkiewicz J, Lehman J, Raska K Jr, Voelkerding K, Mannino RJ. Chimerasome-mediated gene transfer in vitro and in vivo. Gene 1989; 84: 429-438.
109. El Guink N, Kris R, Goodman-Snitkoff GW, Small PA, Mannino RJ. Intranasal immunization with proteoliposomes protects against influenza. Vaccine 1989; 7: 147-151.
110. Gould-Fogerite S, Mannino RJ. Targeted fusogenic liposomes: Functional reconstitution of membrane proteins into large unilamellar vesicles via protein-cochleate intermediates. In: Gregoriadis G, Ed. Liposome Technology. 2nd ed. CRC Press: Boca Raton, FL 1992; III, 262-275.
111. Gould-Fogerite S, Edghill-Smith Y, Kheiri M, et al. Lipid matrixparasitic, based subunit vaccines: A structure-function approach to oral and parenteral immunization. AIDS Res Hum Retroviruses 1994; 10s: 99-104.
112. Gould-Fogerite, S., Mannino, R.J.: US5994318 (1999).
113. Metcalfe IC, Glück R. Virosomes for vaccine delivery. In: Schijns VEJC, O'Hagan DT, Eds. Immunopotentiators in modern vaccines. Academic Press: Burlington, MA 2006; 179-189.
114. Grgacic EVL, Anderson DA. Virus-like particles: Passport to immune recognition. Methods 2006; 40: 60-65.
115. Huckriede A, Bungener L, ter Veer W, et al. Influenza virosomes: Combining optimal presentation of hemagglutinin with immunopotentiating activity. Vaccine 2003; 21: 925-931.
116. Bachmann MF, Hengartner H, Zinkernagel RM. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: Role of antigen patterns in B cell induction? Eur J Immunol 1995; 25: 3445-3451.
117. Gluck R. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine 1999; 17: 1782-1787.
118. Huckriede, A.L.W., De Jonge, J.M., Stegmann, A. J. H., Schoen, P.J., Wilschut, J. C.: US20060228376A1 (2006).
119. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mort Wkly Rep Recomm Rep 2005; 54: 1-21.
120. Gluck R. Immunopotentiating reconstituted Influenza Virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine 1992; 10: 915-919.
121. Langley JM, Halperin SA, McNeil S, et al. Safety and immunogenicity of a proteosome(TM)-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine 2006; 24: 1601-1608.
122. Treanor J, Nolan C, O'Brien D, et al. Intranasal administration of a proteosome-influenza vaccine is well tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006; 24: 254-262.
123. Mallett CP, Hale TL, Kaminski RW, et al. Intranasal or intragastric immunization with proteosome-shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of shigella infection. Infection Immun 1995; 63(6) 2382-2386.
124. Burt, D.S., Jones, D.H., Lowell, G.H., White, G.L., Torossian, K., Louis III, F.F., Plante, M.: US20010053368A1 (2001).
125. Krishnan L, Dicaire CJ, Patel GB, Sprott GD. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: Comparison to conventional liposomes and alum. Infect Immun 2000; 68: 54-63.
126. Firtel M, Southam G, Harauz G, Beveridge TJ. Characterization of the cell wall of the sheathed methanogen Methanospirillum hungatei GP1 as an S layer. J Bacteriol 1993; 175(23): 7550-7560.
127. Ennis FA, Cruz J, Jameson J, Klein J, Burt D, Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 1999; 259: 256-261.
128. Frazer IH, Quinn M, Nicklin JL, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX(TM) adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004; 23: 172-181.
129. Ronnberg B, Fekadu M, Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix. Vaccine 1995; 13: 1375-1382.
130. Rimmelzwaan GF, Baars M, van Amerongen G, van Beek R, Osterhaus AD. A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine 2001; 20: 158-163.
131. Barr IG, Sjolander A, Cox JC. ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 1998; 32: 247-271.
132. Mowat AM. Dendritic cells and immune responses to orally administered antigens. Vaccine 2005; 23: 1797-1799.
133. Skene CD, Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods 2006; 40: 53-59.
134. Lenarczyk A, Le TT, Drane D, et al. ISCOM based vaccines for cancer immunotherapy. Vaccine 2004; 22: 963-974.
135. Lendemans DG, Myschik J, Hook S, Rades T. Cationic cage-like complexes formed by DC cholesterol, Quil-A, and phospholipid. J Pharm Sci 2005; 94: 1794-1807.
136. Pearse MJ. Drane D. ISCOMATRIX adjuvant: A potent inducer of humoral and cellular immune responses. Vaccine 2004; 22: 2391-2395.
137. Pinitkiatisakul S, Friedman M, Wikman M, et al. Immunogenicity and protective effect against murine cerebral neosporosis of recombinant NcSRS2 in different ISCOM formulations. Vaccine 2007; 25: 3658-3668.
138. Yoshioka T, Stenberg B, Florence AT. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (span 20, 40, 60 and 80) and a sorbitan triester (span 85). Int J Pharm 1994; 105: 1-6.
139. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998; 172: 33-70.
140. Brewer JM, Roberts CW, O'Grady JE, Smart CJ, Alexander J. Non-ionic surfactant vesicles as vaccine delivery systems. ICHEME-Second Conf. on Indust Immunol 1994: 34-36.
141. Brewer JM, Alexander J. Studies on the adjuvant activity of non-ionic surfactant vesicles: Adjuvant-driven IgG2a production independent of MHC control. Vaccine 1994; 12: 613-619.
142. Jain S, Singh P, Mishra V, Vyas SP. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against Hepatitis B. Immunol Lett 2005; 101: 41-49.
143. Brewer JM, Roberts CW, Conacher M, McColl J, Blaney BA, Alexander J. An adjuvant formulation that preferentially induces T helper cell type 1 cytokine and CD8+ cytotoxic responses is associated with up-regulation of IL-12 and suppression of IL-10 production. Vaccine Res 1996; 5: 77-89.
144. Alexander, J., Brewer, J.M.: US005679355A (1997).
145. Sizer PJH. Towards an oral influenza vaccine. Trends Biotechnol 1997; 15(8): 282-285.
146. Aungst BJ, Saitoh H, Burcham DL, Huang SM, Mousa A, Hussain A. Enhancement of the intestinal absorption of peptides and nonpeptides. J Control Release 1996; 41: 19-31.
147. Senior K. Bilosomes: The answer to oral vaccine delivery? Drug Discov Today 2001; 6 (20): 1031-1032.
148. Childers NK, Michalek SM. Liposomes. In: O'Hagan DT, Ed. Novel delivery systems for oral vaccines. CRC Press: Boca Raton FL 1994; 175-205.
149. des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release 2006; 116: 1-27.
150. Challacombe SJ, Rahman D, O'Hagan DT. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine 1997; 15(2): 169-175.
151. Damgé C, Michel C. Aprahamian M, Couvreur P. New approach for oral administration of insulin with poly- alkycyanoacrylate nanocapsules as drug carrier. Diabetes 1988; 37: 246-251.
152. Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev 1991; 7: 71-86.
153. Kreuter J. Nanoparticles as adjuvants for vaccines. In: Powell MF, Newman MJ, Eds. Vaccine design. The subunit and adjuvant approach. Plenum Press: New York 1995; 463-472.
154. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 1995; 12: 1-99.
155. Putney SD. Burke PA. Improving protein therapeutics with sustained-release formulations. Nat Biotechnol 1998; 16: 153-157.
156. Katz DE, DeLorimier AJ, Wolf MK, et al. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 2003; 21: 341-346.
157. Santiago N, Milstein S, Rivera T, et al. Oral Immunization of rats with proteinoid microspheres encapsulating influenza virus antigens. Pharm Res 1993; 10(8): 1243-1247.
158. Bowersock TL. Uptake of alginate microspheres by Peyer's patches. Proc Int Symp Control Release Bioact Mater. 1994; 21: 839-840.
159. Artursson P, Martensson IL, Sjoholm I. Biodegradable microspheres III. Some immunological properties of polyacryl starch microspheres. J Pharm Sci 1986; 75: 697-701.
160. Schroder U, Stahl A. Crystallised dextran nanospheres with entrapped antigen and their use as adjuvants. J Immunol Methods 1984; 70: 127-132.
161. O'Hagan DT. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev 1998; 34: 305-320.
162. Eldridge JH, Meulbroek JA, Staas JK, Tice TR, Gilley RM. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol 1989; 251: 191-202.
163. Lutsiak ME, Robinson DR, Coester C, Kwon GS, Samuel J. Analysis of poly(d,l-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 2002; 19: 1480-1487.
164. Newman KD, Elamanchili P, Kwon GS, Samuel J. Uptake of poly (d,l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater. Res 2002; 60: 480-486.
165. Wise, D.L., Trantolo, D.J., Hile, D.D., Doherty, S.A.: US20040013688A1 (2004).
166. Sjoholm, I., Wikingsson, L.D.: US20030211122A1 (2003).
167. Alpar, H.O., Eyles, J.E., Somavarapu, S., Williamson, E.D., Baillie, L.W.J.: 20080057083A1 (2008).
168. Illum L. Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems? J Pharm Sci 2007; 96(3): 473-483.
169. des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release 2006; 116(1): 1-27.
170. Frey, A., Neutra, M.R., Robey, F.A.: US20006086881 (2000).
171. Speaker, T.J., Sultzbaugh, K. J.: US5686113 (1997).
172. Roy, K., Huang, S-K., Sampson, H., Leong, K.W.: US20026475995 (2002).
173. Schwendeman, S., Cui, C.: US20016326021 (2001).
174. Irache Garreta, J.M., Yoncheva, K.P.: US20080248125A1 (2008).
175. Alonso, F. M.J., Janes, K., Csaba, N.: US20080095810A1 (2008).
176. De Los, R.M.A., Oh, K.J.: US20060292174A1(2006).
177. Liu LM, MacPherson GG. Lymph-borne (veiled) dendritic cells can acquire and present intestinally administered antigens. Immunology 1991; 73: 281-286.
178. Liu LM, MacPherson GG. Antigen acquisition by dendritic cells: Intestinal dendritic cells acquire antigen administered orally and can prime naive T cells in vivo. J Exp Med 1993; 177: 1299-1307.
179. Rey J, Garin N, Spertini F, Corthesy B. Targeting of secretory IgA to Peyer's patch dendritic and T cells after transport by intestinal M cell. J Immunol 2004; 172: 3026-3033.
180. Mantis NJ, Cheung MC, Chintalacharuvu KR, Rey J, Corthesy B, Neutra MR. Selective adherence of IgA to murine Peyer's patch M cells: Evidence for a novel IgA receptor. J Immunol 2002; 169: 1844-1851.
181. Sugimoto M, Ohishi K, Fukasawa M, et al. Oligomannose-coated liposomes as an adjuvant for the induction of cell-mediated immunity. FEBS Lett 1995; 363: 53-56.
182. Fukasawa M, Shimizu Y, Shikata K, et al. Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes. FEBS Lett 1998; 441: 353-356.
183. Copland MJ, Baird MA, Rades T, et al. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003; 21: 883-890.
184. Arigita C, Bevaart L, Everse LA, et al. Liposomal meningococcal B vaccination: Role of dendritic cell targeting in the development of a protective immune response. Infect Immun 2003; 71: 5210-5218.
185. Mestecky J, Michalek SM, Moldoveanu Z, Russell MW. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans. Behring Inst Mitt 1997; 98: 33-43.
186. Williams NA, Hirst TR, Nashar TO. Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic. Immunol Today 1999; 20: 95-101.
187. Frey A, Neutra MR. Targeting of mucosal vaccines to Peyer's patch M cells. Behring Inst Mitt 1997; 98: 376-389.
188. Neutra MR, Mantis NJ, Frey A, Giannasca PJ. The composition and function of M cell apical membranes: Implications for microbial pathogenesis. Semin Immunol 1999; 11: 171-181.
189. Frey A, Giannasca KT, Weltzin R, et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: Implications for microbial attachment and oral vaccine targeting. J Exp Med 1996; 184: 1045-1059.
190. Mantis NJ, Frey A, Neutra MR. Accessibility of glycolipid and oligosaccharide epitopes on rabbit villus and phosphatidylserfollicle-associated epithelium. Am J Physiol Gastrointest Liver Physiol 2000; 278: G915-G923.
191. Harokopakis E, Hajishengallis G, Michalek SM. Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect Immun 1998; 66: 4299-4304.
192. Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target 2007; 15(10): 701-713.
193. Gupta PN, Mahor S, Rawat A, Khatri K, Goyal A, Vyas SP. Lectin anchored stabilized biodegradable nanoparticles for oral immunization development and in vitro evaluation. Int J Pharm 2006; 318(1-2): 163-173.